Chiriac, U.; Liebchen, U.; Frey, O.R.; Lanzinger, H.; Klein, S.; Hoppe-Tichy, T.; Karck, M.; Meyer, A.; Morath, B.
Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections. Antibiotics 2024, 13, 1103.
https://doi.org/10.3390/antibiotics13111103
AMA Style
Chiriac U, Liebchen U, Frey OR, Lanzinger H, Klein S, Hoppe-Tichy T, Karck M, Meyer A, Morath B.
Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections. Antibiotics. 2024; 13(11):1103.
https://doi.org/10.3390/antibiotics13111103
Chicago/Turabian Style
Chiriac, Ute, Uwe Liebchen, Otto Roman Frey, Heike Lanzinger, Sabrina Klein, Torsten Hoppe-Tichy, Matthias Karck, Anna Meyer, and Benedict Morath.
2024. "Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections" Antibiotics 13, no. 11: 1103.
https://doi.org/10.3390/antibiotics13111103
APA Style
Chiriac, U., Liebchen, U., Frey, O. R., Lanzinger, H., Klein, S., Hoppe-Tichy, T., Karck, M., Meyer, A., & Morath, B.
(2024). Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections. Antibiotics, 13(11), 1103.
https://doi.org/10.3390/antibiotics13111103
